FIA
BCTX

FNY Investment Advisers’s Briacell Therapeutics BCTX Stock Holding History

FNY Investment Advisers’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Hold
10
– – ﹤0.01% 872
2026
Q1 		$0 Hold
10
– – ﹤0.01% 783
2025
Q4 		$0 Hold
10
– – ﹤0.01% 951
2025
Q3 		$0 Hold
10
– – ﹤0.01% 1246
2025
Q2 		$0 Sell
10
-10
-50% -$365 ﹤0.01% 971
2025
Q1 		$0 Buy
20
+10
+100% +$477 ﹤0.01% 737
2024
Q4 		$0 Buy
+10
New +$1.2K ﹤0.01% 672
2021
Q4 		– Sell
-31
Closed -$37K – 561
2021
Q3 		$37K Buy
+31
New +$28.5K 0.02% 407

Other funds holding BCTX

IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
HWA
HHM Wealth Advisors Chattanooga, Tennessee $996M AUM 23.11% 1-Year Est. Return

FNY Investment Advisers's BCTX Position: Q2 2026 in Review

FNY Investment Advisers held its Briacell Therapeutics (BCTX) position steady in Q2 2026 at 10 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #872.

FNY Investment Advisers first reported a position in BCTX in Q3 2021 and has held it in 8 quarters since. The position peaked at $37K in Q3 2021. 4 funds tracked by Wall St. Rank hold BCTX as of Q2 2026.

  • FNY Investment Advisers held 10 shares of Briacell Therapeutics worth $0 as of Q2 2026.
  • FNY Investment Advisers left its Briacell Therapeutics share count unchanged in Q2 2026.
  • Briacell Therapeutics made up ﹤0.01% of FNY Investment Advisers's portfolio in Q2 2026, its #872 holding.
  • FNY Investment Advisers first reported a position in Briacell Therapeutics in Q3 2021 and has held it in 8 quarters since.
  • FNY Investment Advisers's Briacell Therapeutics position peaked at $37K in Q3 2021.
  • 4 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.